Terapi Profilaksis versus On-Demand pada Pasien Hemofilia Berat dengan Hemartrosis
Sari
Hemartrosis merupakan komplikasi perdarahan sendi yang paling sering terjadi pada pasien dengan hemofilia
A, bila penanganan tidak adekuat maka kelainan sendi akan menjadi kronik dan menetap bahkan memburuk.
Dilaporkan seorang anak lali-laki 14 tahun dengan diagnosis Hemofilia A sejak berusia 4 bulan. Keluhan
nyeri dan bengkak sendi lutut dirasakan sejak tujuh tahun yang lalu. Pengobatan dengan pemberian faktor
VIII konsentrat diberikan sesuai dengan kebutuhan, bila ada perdarahan (on-demand). Pada evaluasi foto
radiologis menunjukkan gambaran artropati kronis lutut kanan. Artropati kronis seyogyanya dapat dicegah
bila pemberian faktor VIII konsentrat secara rutin sebagai pencegahan hematrosis. Namun terdapat kesulitan
karena keterbatasan penyediaan obat di Indonesia
Kata Kunci
Teks Lengkap:
PDFReferensi
World Federation of Hemophilia. Guidelines for the
management of hemophilia. Montreal: World Federation
of Hemophilia, 2005.
Bell B, Canty D, Audet M. Hemophilia: An updated
review. Pediatr Rev 1995;16:290-8.
Stobart K, Iorio A, Wu JK. Clotting factor concentrates
given to prevent bleeding and bleeding related
complications in people with hemophilia A or B.
Cochrane Database of Syst Rev. 2006;2:CD003429.
Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske
B, Hacker MR, Kilcoyne R, dkk. Prophylaxis versus
episodic treatment to prevent joint disease in boys with
severe hemophilia. N Engl J Med 2007;6:535-44.
Oxford Centre of Evidence-based Medicine. Oxford
Centre for Evidence-based Medicine Levels of Evidence
(March 2009). Diunduh dari: http://www.cebm.net/index.
asox?o=1025. Diakses tanggal 9 Juni 2009.
Nillson IM, Berntorp E, Löfqvist T, Pettersson H.
Twenty-five years experience of prophylactic treatment in
severe haemophilia A and B. J Intern Med 1992;232:25-
Ljung R. Prevention of bleeding in haemophilia: Trends,
overcoming barriers and future treatment options.
Haemophilia 2007;13 (Suppl 2):1-3.
Royal S, Schramm W, Berntorp E, Giangrande P,
Gringeri A, Ludlam C, dkk. Quality-of-life differences
between prophylactic and on-demand factor replacement
therapy in European haemophilia patients. Haemophilia
;8:44–50.
Kreuz W, Escuriola-Ettingshausen C, Funk M, Schmidt H, Kornhuber B. When should prophylactic treatment
in patients with haemophilia A and B start? The German
experience. Haemophilia 1998;4:413-7.
Van den Berg HM, Fischer K, Mauser-Bunschoten
EP, Beek FJA, Roosendaal G, van der Bom JG. Longterm
outcome of individualized prophylactic treatment
of children with severe haemophilia. Br J Haematol
;112:561-5.
Fischer K, Grobbee DE, van den Berg HM. RCTs
and observational studies to determine the effect
of prophylaxis in severe haemophilia. Haemophilia
;13:245-50.
Manucci PM. Need for randomized trials in haemophilia.
J Thromb Haemost 2006;4:501-2.
Gringeri A. Prospective controlled study on prophylaxis:
An Italian approach. Haemophilia 2003;9(Suppl 1):38-
Indonesian Hemophilia Society. The golden standard
theraphy for hemophilia A (Factor VIII). Diunduh dari
http://www.hemofilia.or.id/koate.php. Diakses tanggal 11 Juni
Srivastava A, You SK, Ayob Y, Chuansumrit A, de Bosch
N, Bianco RP, dkk. Hemophilia treatment in developing
countries: Products and protocols. Semin Thromb
Hemost 2005;31:495-500.
Gilham A. Guideline for the Treatment of Haemophilia
in South Africa. SAMJ 2007;97:1296-311.
Petrini P. What factors should influence the dosage and
interval of prophylactic treatment in patients with severe
hemophilia A and B? Haemophilia 2001;7:99-102.
DOI: http://dx.doi.org/10.14238/sp11.5.2010.311-6
Refbacks
- Saat ini tidak ada refbacks.
##submission.copyrightStatement##
##submission.license.cc.by-nc-sa4.footer##
Email: editorial [at] saripediatri.org
Sari Pediatri diterbitkan oleh Badan Penerbit Ikatan Dokter Anak Indonesia
Ciptaan disebarluaskan di bawah Lisensi Creative Commons Atribusi-NonKomersial-BerbagiSerupa 4.0 Internasional.